64 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
4
Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent.
Allergan
7
Synthesis and biological activity of retinoic acid receptor-alpha specific amides.
Allergan
4
Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes.
Allergan
9
Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.
Allergan
6
A new class of potent RAR antagonists: dihydroanthracenyl, benzochromenyl and benzothiochromenyl retinoids.
Allergan
4
Stereoselective synthesis and receptor activity of conformationally defined retinoid X receptor selective ligands.
Allergan
14
Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists.
Allergan
8
Synthesis and structure-activity relationships of retinoid X receptor selective diaryl sulfide analogs of retinoic acid.
Allergan
5
Synthesis and evaluation of 2-[(5-methylbenz-1-ox-4-azin-6-yl)imino]imidazoline, a potent, peripherally acting alpha 2 adrenoceptor agonist.
Allergan
15
Synthesis and carbonic anhydrase inhibitory activity of 4-substituted 2-thiophenesulfonamides.
Allergan
10
Synthesis and structure-activity relationships of stilbene retinoid analogs substituted with heteroaromatic carboxylic acids.
Allergan
2
Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors.
Allergan
6
Identification of highly potent retinoic acid receptor alpha-selective antagonists.
Allergan
179
Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
Allergan
179
Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
Allergan
187
Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
Allergan
11
Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives
Allergan
83
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Allergan
7
Substituted 1,2,3,4-tetrahydropyrido[3,4-E] pyrrolo[1,2-A]pyrimidines as kinase
Allergan
17
Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
Allergan
42
Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
Allergan
8
Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors
Allergan
167
Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
Allergan
29
3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
Allergan
84
Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
Allergan
154
6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
Allergan